Stocks › OGN
Organon & Co.
OGN·NYSE·
United States·USD
$13.89
-0.02 (-0.14%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
OGN
Organon & Co. · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
OGNS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of OGN by members of U.S. Congress · 28 on record · 3 in the last 12 months
Whale Activity
Position changes in OGN reported for 2026-09-30 by 666 institutional filers
- Increased147
- New47
- Held187
- Decreased181
- Closed66
- No prior filing38
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 31.9M | $437.3M | decreased |
| Pentwater Capital Management LP | 20.2M | $276.5M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 15.4M | $210.3M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 11.9M | $163.3M | increased |
| FIL Ltd | 10.5M | $143.9M | new |
| STATE STREET CORP | 9.8M | $133.7M | increased |
| MILLENNIUM MANAGEMENT LLC | 5.1M | $70.4M | increased |
| ALLIANCEBERNSTEIN L.P. | 4.8M | $65.9M | increased |
| Man Group plc | 4.8M | $65.9M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 4.6M | $63.6M | decreased |
| UBS Group AG | 4.5M | $61.0M | decreased |
| NEXPOINT ASSET MANAGEMENT, L.P. | 4.4M | $60.3M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by OGN insiders, by quarter · Form 4
Recent Insider Transactions
446 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Arjona Ferreira Juan CamiloHead of R&D & CMO | Tax withholding | −4,134 | $13.62 | $56K | Aug 11, 2026 | Form 4 ↗ |
| Arjona Ferreira Juan CamiloHead of R&D & CMO | Option exercise | +11.5K | $0.00 | $0 | Aug 11, 2026 | Form 4 ↗ |
| Drinane Juliana PapaHead of Mfg & Supply | Sale | −14.8K | $13.57 | $200K | Aug 5, 2026 | Form 4 ↗ |
| Holzbaur LynetteSVP and Corporate Controller | Sale Amended | −26.4K | $13.35 | $353K | May 6, 2026 | Form 4 ↗ |
| Holzbaur LynetteSVP and Corporate Controller | Other Amended | +46 | $0.00 | $0 | May 6, 2026 | Form 4 ↗ |
| Holzbaur LynetteSVP and Corporate Controller | Purchase | +26.4K | $13.35 | $353K | May 6, 2026 | Form 4 ↗ |
| Drinane Juliana PapaInterim Head of Mfg & Supply | Tax withholding | −3,451 | $5.70 | $20K | Mar 31, 2026 | Form 4 ↗ |
| Drinane Juliana PapaInterim Head of Mfg & Supply | Option exercise | +10.1K | $0.00 | $0 | Mar 31, 2026 | Form 4 ↗ |
| Drinane Juliana PapaInterim Head of Mfg & Supply | Tax withholding | −2,185 | $5.70 | $12K | Mar 31, 2026 | Form 4 ↗ |
| Drinane Juliana PapaInterim Head of Mfg & Supply | Option exercise | +6,378 | $0.00 | $0 | Mar 31, 2026 | Form 4 ↗ |
| Arjona Ferreira Juan CamiloHead of R&D & CMO | Tax withholding | −4,820 | $5.70 | $27K | Mar 31, 2026 | Form 4 ↗ |
| Arjona Ferreira Juan CamiloHead of R&D & CMO | Option exercise | +13.4K | $0.00 | $0 | Mar 31, 2026 | Form 4 ↗ |
| Karp DanielExecutive VP, Corp. Dev. | Tax withholding | −2,105 | $5.70 | $12K | Mar 31, 2026 | Form 4 ↗ |
| Karp DanielExecutive VP, Corp. Dev. | Option exercise | +6,715 | $0.00 | $0 | Mar 31, 2026 | Form 4 ↗ |
| Karp DanielExecutive VP, Corp. Dev. | Tax withholding | −3,554 | $5.70 | $20K | Mar 31, 2026 | Form 4 ↗ |
| Karp DanielExecutive VP, Corp. Dev. | Option exercise | +11.3K | $0.00 | $0 | Mar 31, 2026 | Form 4 ↗ |
| Stahler Rachel AChief Information Officer | Tax withholding | −4,217 | $5.70 | $24K | Mar 31, 2026 | Form 4 ↗ |
| Stahler Rachel AChief Information Officer | Option exercise | +12.3K | $0.00 | $0 | Mar 31, 2026 | Form 4 ↗ |
| Stahler Rachel AChief Information Officer | Tax withholding | −2,246 | $5.70 | $13K | Mar 31, 2026 | Form 4 ↗ |
| Stahler Rachel AChief Information Officer | Option exercise | +6,555 | $0.00 | $0 | Mar 31, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding OGN · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 15.8M | $214.2M | 0.19% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 8.3M | $112.8M | 0.00% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 6.0M | $81.6M | 0.04% | Jun 30, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 3.8M | $51.7M | 0.08% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.0M | $40.8M | 0.04% | Jun 30, 2026 |
| Nexpoint Merger Arbitrage Fund NexPoint Funds I | 2.7M | $36.6M | 2.46% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF SPDR SERIES TRUST | 2.4M | $32.7M | 0.19% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Value ETF iShares Trust | 2.3M | $30.6M | 0.38% | Jun 30, 2026 |
| State Street(R) SPDR(R) S & P 600(TM) Small Cap Value ETF SPDR SERIES TRUST | 1.4M | $18.5M | 0.38% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 1.3M | $17.6M | 0.04% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list OGN's shares (CUSIP 68622V106), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming organon as client
- WILLIAMS AND JENSEN, PLLCORGANON · 2026 Q3 · HCR, BUD$50K
Filing ↗ - ORGANON & CO.ORGANON & CO. · 2026 Q3 · BUD, HCR, MMM$340K
Filing ↗ - TIBER CREEK GROUPORGANON, LLC · 2026 Q3 · HCR, BUD, MMM$60K
Filing ↗ - JEFFREY J. KIMBELL & ASSOCIATES, INC.ORGANON & CO. · 2026 Q3 · HCR, MMM$5K
Filing ↗ - WILLIAMS AND JENSEN, PLLCORGANON · 2026 Q2 · BUD, HCR$50K
Filing ↗
Government Contracts
Federal awards to Organon & Co. · USAspending
No federal contract awards found for Organon & Co..
U.S. Patents
Recent USPTO applications naming Organon & Co.
No USPTO patent applications found for Organon & Co..
Annual Financials
From OGN's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B |
| Net income | $187.0M | $864.0M | $1.02B | $917.0M | $1.35B |
| Diluted EPS | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 |
| Operating cash flow | $700.0M | $939.0M | $799.0M | $858.0M | n/a |
| Cash and equivalents | $574.0M | $675.0M | $693.0M | $706.0M | $737.0M |
| Total assets | $12.87B | $13.10B | $12.06B | $10.96B | $10.68B |
| Total liabilities | $12.12B | $12.63B | $12.13B | $11.85B | n/a |
| Shareholders' equity | $752.0M | $472.0M | -$70.0M | -$892.0M | -$1.51B |
As Organon & Co. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 24, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in OGN's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 9.01Reg FD disclosureOct 30, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureJul 31, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJul 23, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJul 17, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 11, 2026
EDGAR ↗
About Organon & Co.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersJERSEY CITY, NJ
SEC CIK0001821825 ↗




